Femasys stock.

Sep 29, 2023 · Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 14. CI. Earnings Flash (FEMY) FEMASYS Reports Q3 Revenue $86,186. Nov. 14. MT. Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc. Nov. 13. Oct 2, 2023 · What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ... Dec 31, 2022 · Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors Chuck Padala LifeSci Advisors, LLC +1-917-741-7792 [email protected]. Femasys Inc. Investor Contact: [email protected]. Media Contact ... Femasys has a market capitalisation of US$22m and burnt through US$11m last year, ... It does not constitute a recommendation to buy or sell any stock, ...John Dyett has not been actively trading shares of Femasys over the course of the past ninety days. Most recently, on Wednesday, June 23rd, John Dyett bought 53,500 shares of Femasys stock. The stock was acquired at an average cost of $12.93 per share, with a total value of $691,755.00. Learn More on John Dyett's trading history.

Femasys’ FemaSeed ® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared (and also approved in Canada). The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada and ...The stock is up ~205% in after-hours trading on Monday. Femasys (FEMY) says that FeedSeed is "less invasive and more affordable than assisted reproduction procedures, such as in vitro ...

FEMY - Femasys Inc Stock Price and Quote. Nov-23-23 03:38PM. 20 Countries with the Highest Teenage Pregnancy Rates. (Insider Monkey) Nov-15-23 08:30AM. PharmaCyte Biotech Acquires $5 Million Stake in Emerging Womens Health Innovator Femasys, Inc. Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by ...Dec 1, 2023 · Stock analysis for Femasys Inc (FEMY:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Finally, UBS Group AG grew its holdings in Femasys by 6,394.8% during the first quarter. UBS Group AG now owns 66,702 shares of the company’s stock valued at $151,000 after purchasing an additional 65,675 shares during the period. Institutional investors and hedge funds own 8.29% of the company’s stock. About Femasys (Get …Nov 15, 2023 · These promising developments of Femasys’s products further solidify the Buy rating. In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price ... FEMASYS INC. EMPLOYEE STOCK PURCHASE PLAN 1. SECTION 1. PURPOSE OF THE PLAN. The Femasys Inc. Employee Stock Purchase Plan (the “Plan”) is intended to provide Eligible Employees (as defined below) the opportunity to increase their proprietary interest in Femasys Inc. (the “Company”) by conveniently purchasing shares of the …Based on short-term price targets offered by three analysts, the average price target for Femasys Inc. comes to $9.00. The forecasts range from a low of $5.00 to a high of $12.00. The average ...FEMY | Complete Femasys Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ...

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ...

The stock is up ~205% in after-hours trading on Monday. Femasys (FEMY) says that FeedSeed is "less invasive and more affordable than assisted reproduction procedures, such as in vitro ...Find the latest Femasys Inc. (FEMY) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Aug 10, 2023 · Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update. August 10, 2023 08:00 ET ... Common stock, $.001 par, 200,000,000 authorized, ... Oct 24, 2023 · Femasys is a commercial-stage company with four approved products — FemaSeed (intratubal Insemination), FemVue (contrast generating device), FemCath (selective delivery catheter) and FemCerv ... ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …Nov 28, 2023 · What is the target price for Femasys (FEMY) stock? The latest price target for Femasys ( NASDAQ: FEMY) was reported by HC Wainwright & Co. on Tuesday, November 14, 2023. The analyst firm set a ...

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Stock Price Targets. High, $12.00. Median, $8.50. Low, $5.00. Average, $8.50. Current Price, $0.9522. Yearly Numbers. Estimates. FEMY will report 2023 earnings ...Dec 1, 2023 · Stock analysis for Femasys Inc (FEMY:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Femasys Inc. Common Stock (FEMY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Zacks Rank: FEMY currently carries a Zacks Rank #3. Femasys Inc. Price and Consensus. Femasys Inc. price-consensus-chart | Femasys Inc. Quote. Stocks to Consider. Here are some stocks in the same ...Nov 29, 2023 · 3 equities research analysts have issued twelve-month price targets for Femasys' shares. Their FEMY share price targets range from $7.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 884.9% from the stock's current price. View analysts price targets for FEMY or ...

Get the latest Femasys Inc (FEMY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Femasys Inc. FEMY shares are up more than 14% on Monday and have gained more than 900% over the last five days. Here's a look at what's going on:. What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday.. Femasys also announced last …

PharmaCyte Biotech makes $5M investment in Femasys to utilize cash position. The Fly 12 days ago. Track Femasys Inc (FEMY) Stock Price, Quote, latest community messages, …WebNov 15, 2023 · These promising developments of Femasys’s products further solidify the Buy rating. In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price ... Nov 29, 2023 · Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M SA News Thu, Aug. 10 Femsys stock jumps 21% after FDA green lights FemBloc testing Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.Stock Info Stock Quote Price $1.03 Volume 3,368,658 Change +0.12 % Change +12.72% Today's Open $0.96 Previous Close $0.91 Intraday High $1.14 Intraday …WebAt Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

Femasys (FEMY) Short Interest Ratio and Volume 2023. DOW 35,390.15. QQQ 389.51. Turned down for a loan, business owners look to family and even crowdsourcing to get money to grow. Important info on NVDA trade (Ad) 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas.

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.15 nov 2023 ... ... shares of common stock at $1.18 per share, expiring one year from issuance, and warrants to purchase approximately 5.8 million shares of ...Nov 30, 2023 · Read Full Company Summary for FEMY here. View Femasys Inc FEMY investment & stock information. Get the latest Femasys Inc FEMY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.Find the latest Earnings Report Date for Femasys Inc. Common Stock (FEMY) at Nasdaq.com.Sep 27, 2023 · Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including FemaSeed ® an FDA- cleared infertility treatment, FemBloc ® a lead late-clinical stage product candidate for permanent birth control, and FDA-cleared, innovative diagnostic products. Femasys has a market capitalisation of US$22m and burnt through US$11m last year, which is 50% of the company's market value. ... It does not constitute a recommendation to buy or sell any stock ...An Atlanta woman-founded, women's healthcare company plans to raise $40 million in an initial public stock offering. Suwanee-based Femasys Inc. says in plans filed May 14 with the Securities and ...FEMY - Femasys Inc Stock Price and Quote Nov-23-23 03:38PM 20 Countries with the Highest Teenage Pregnancy Rates (Insider Monkey) Nov-15-23 08:30AM PharmaCyte …Web

Track Femasys Inc (FEMY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors View live Femasys Inc. chart to track its stock's price action. Find market predictions, FEMY financials and market news. ... Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare.Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerWebInstagram:https://instagram. stock under 5 dollarsfirst solar.schwab best index fundsbetting odds for president 2024 Femasys Inc ( FEMY) has fallen Tuesday morning, with the stock losing -1.54% in pre-market trading to 1.28. FEMY's short-term technical score of 47 indicates that the stock has traded less bullishly over the last month than 53% of stocks on the market. In the Medical Instruments & Supplies industry, which ranks 80 out of 146 industries, …- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception … vanguard admiral healthcare fundrare united states quarters Femasys Inc Follow Share $1.03 After Hours: $1.06 (2.91%) +0.030 Closed: Nov 24, 4:59:11 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Soleno Therapeutics Inc $28.87 SLNO3.11% Novo... Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an …Web aarp dental insurance review Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.See the company profile for Femasys Inc. (FEMY) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.